Navigation Links
Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
Date:7/21/2008

x assets and related valuation allowance) and liabilities of Old Lorus were transferred to the Company and/or its subsidiaries. The Company continued the business of Old Lorus after the Arrangement Date with the same officers and employees and continued to be governed by the same Board of Directors as Old Lorus prior to the Arrangement Date. Therefore, the Company's operations have been accounted for on a continuity of interest basis and accordingly, the consolidated financial statement information above reflect that of the Company as if it had always carried on the business formerly carried on by Old Lorus.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: financings and corporate reorganizations, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "expect", "intend", "will", "should", "would", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us ar
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Lorus Therapeutics Receives $600 Thousand From Escrow Account
2. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
3. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
4. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
7. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
8. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
11. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... ... The global aptamers market is expected to reach $244.93 ... 17.89% between 2015 and 2020. The aptamer type segments included in this report ... is segmented into diagnostics, therapeutics development, R&D, and other applications. Diagnostics applications will ...
(Date:7/7/2015)... Pensacola, FL (PRWEB) , ... July 07, 2015 ... ... trials, ActiGraph’s CentrePoint Study Admin system was developed to solve many ... collection and analysis, particularly within studies that involve multiple clinical sites and/or remote ...
(Date:7/6/2015)... ... July 06, 2015 , ... A study by a ... how virulent fungi adapt through genetic modifications to fight back against the effects ... temporarily weakened. These insights may provide clues to new ways to treat notoriously ...
(Date:7/6/2015)... , July 6, 2015  Emdeon ... into a definitive agreement to acquire Altegra ... intervention platforms that combine data aggregation and ... capabilities to achieve actionable insights and improved ... combine Altegra Health,s risk adjustment and quality ...
Breaking Biology Technology:Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 2Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 4Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 5ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 2ActiGraph Launches CentrePoint Cloud-based Study Management Software Platform 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4Emdeon to Acquire Altegra Health 2Emdeon to Acquire Altegra Health 3Emdeon to Acquire Altegra Health 4
... Broad Institute of MIT and Harvard Deploys Isilon ... Expansion, Enabling Five-Fold Data Growth, SEATTLE, Sept. ... clustered storage, today announced that the Broad,Institute of ... genomics and,biomedical research institutes, has deployed Isilon IQ ...
... VEENENDAAL, Netherlands, September 15 , - Oncentra(R) ... in,Gothenburg, Sweden, September 14-18 and ASTRO 2008, Boston, ... radiation oncology today,announced the market release of Oncentra ... from Nucletron allows clinicians to review,radiotherapy plans that ...
... SYK ) announced that it will host a conference ... Time, to discuss the,Company,s operating results for the quarter ... results for the quarter ended,September 30, 2008 will be ... in the conference call dial 800-299-9630 (domestic) or,617-786-2904 (international) ...
Cached Biology Technology:Isilon IQ Powers Data Storage for Next-Generation DNA Sequencing 2Isilon IQ Powers Data Storage for Next-Generation DNA Sequencing 3Nucletron Announces Market Release of First Commercially Available Software to Review and Share Dicom-Based Treatment Plans for Radiotherapy 2Stryker to Host Conference Call on October 16, 2008 2
(Date:6/25/2015)... DALLAS , June 25, 2015 ... report "Fingerprint Sensors Market by Type (Swipe & Area), Technology, ... (Mobile, Government, Healthcare, Commercial Security & Others) & ... published by marketsandmarkets, the said market is expected ... CAGR of 17.1%. Browse 76 ...
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
(Date:6/24/2015)... 2015 This report provides market analysis of ... years. It contains an analysis of the drivers, challenges, ... impact from the short, medium, and long term perspective ... market, and technology trends that currently, prevail in the ... authorities to efficiently manage the increasing marine traffic and ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... JUPITER, FL, August 24, 2010 - Scientists from the Florida campus ... a critical role in the formation of long-term memory. The findings ... and could lead to novel treatments for memory disorders. The ... Neuron on August 26, 2010. In the study, the ...
... receiving an honour, the American entertainer Jack Benny once said, ... I don,t deserve that either." Unfortunately, Benny was not ... Arthritis is associated with significant discomfort and simple activities such ... painful. A variety of treatments are available, usually involving ...
... The results of a new scientific study from Oxford ... different affects on short-term total energy intake in men and ... Ranawana and Professor Jeya Henry of the Functional Food Centre ... to compare the compensation effect of liquid calories on short-term ...
Cached Biology News:Scripps Research scientists uncover new mechanism of memory formation 2A dog's life -- physiotherapy for arthritic pets 2Research shows gender difference in energy compensation effect 2
Mouse monoclonal [CLB-SW16 (formerly 708)] to CD42d (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 2814 SwissProtID: P40197...
Mouse monoclonal [7C6] to Bcr-abl ( Abpromise for all tested applications). SwissProtID: P11274...
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
Biology Products: